Heron Therapeutics, Inc.
NASDAQ:HRTXBiotechnology
+$0.01 today
- Market cap
- $51.94M
- Beta
- 1.57
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.16
Volume 1.81M
Average 2.90M
HRTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Heron Therapeutics, Inc.NASDAQ: HRTX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.98M rose 18.5% year over year, ahead of the -10.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 36.6% from the prior quarter. Over 3 fiscal years it compounded at -37.8% a year.
Context
- Stock-based compensation amounted to 6.7% of revenue in FY2025, down 2.3 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +18.5% holds above the trailing-twelve-month pace of -10.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 10.34M USD
- Year-over-year change
- -20.2%
- 4-year CAGR
- -31.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.34M | -20.2% |
| FY2024 | 2024-12-31 | 12.96M | -60.5% |
| FY2023 | 2023-12-31 | 32.85M | -23.6% |
| FY2022 | 2022-12-31 | 42.98M | -8.3% |
| FY2021 | 2021-12-31 | 46.85M | — |
Stock-Based Compensation vs competitors
How HRTX compares with its peers on the latest reported figures
- HRTX's LTM Mar 2026 stock-based compensation of $10.8M is the 5th largest of the 10 companies compared; the peer median is $4.36M.
- Its year-over-year change of -10.7% is the 3rd highest of 9, against a peer median of -20.5%.
- Stock-based compensation amounts to 7.2% of revenue for HRTX, versus a peer median of 20.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.99M | -15.0% | -30.6% | 46.9% | |
| LTM Mar 2026 | $15.21M | — | — | — | |
| LTM Mar 2026 | $15.02M | -24.7% | -4.8% | 52.0% | |
| LTM Mar 2026 | $11.51M | -33.2% | -18.7% | 20.6% | |
| LTM Mar 2026 | $10.8M | -10.7% | -37.8% | 7.2% | |
| LTM Mar 2026 | $4.36M | +16.7% | -17.0% | — | |
| LTM Sep 2026 | $4.19M | +122.7% | +4.3% | — | |
| LTM Mar 2026 | $2.91M | -16.2% | +16.9% | 20.1% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $1.44M | -63.8% | — | — |
| LTM Mar 2026 | $8K | -100.3% | +3.3% | 0.0% | |
| Peer median (excluding HRTX) | $4.36M | -20.5% | -4.8% | 20.6% | |
Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (220.68M) | (182.02M) | (110.56M) | (13.58M) | (20.2M) |
| Depreciation & Amortization | 3.02M | 2.89M | 2.9M | 2.49M | 2.31M |
| Deferred Income Tax | 1.63M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 46.85M | 42.98M | 32.85M | 12.96M | 10.34M |
| Change in Working Capital | (35.08M) | (10.51M) | 16.79M | (27.6M) | (31.88M) |
| Accounts Receivables | 6.35M | (16.55M) | (8.09M) | (18.74M) | (10.71M) |
| Inventory | (6.48M) | (6.19M) | 12.46M | (11.05M) | (31.05M) |
| Accounts Payables | 3.28M | (578K) | 15K | 8.47M | (2.72M) |
| Other Working Capital | (38.23M) | 12.81M | 12.4M | (6.28M) | 12.59M |
| Other Non-Cash Items | 904K | (251K) | (773K) | 3.2M | 11.83M |
| Operating Cash Flow | (203.35M) | (146.91M) | (58.79M) | (22.53M) | (27.59M) |
| Capital Expenditures | (3.02M) | (1.83M) | (1.55M) | (1.71M) | (317K) |
| Acquisitions (Net) | 32K | 227K | 13K | 27K | 0 |
| Purchases of Investments | (129.22M) | (145.68M) | (87.66M) | (103.09M) | (50.79M) |
| Sales of Investments | 164.94M | 143.96M | 107.19M | 123.48M | 67.01M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 98K |
| Investing Cash Flow | 32.73M | (3.32M) | 18M | 18.71M | 16.01M |
| Debt Repayment | 148.96M | 0 | 24.35M | 0 | 145.11M |
| Common Stock Issued | 7.07M | 75.06M | 29.76M | 940K | 19.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | (150M) |
| Financing Cash Flow | 156.03M | 75.06M | 54.11M | 940K | 14.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (14.6M) | (75.18M) | 13.31M | (2.88M) | 2.85M |
| Free Cash Flow | (206.38M) | (148.74M) | (60.33M) | (24.24M) | (27.91M) |
Heron Therapeutics, Inc.
NASDAQ:HRTX
Intrinsic Alpha fair value
Locked
Current Price
$0.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.